英偉達盤後大漲8.7% 四季度遊戲業務反彈,一季度收入指引優於預期
格隆匯2月23日丨英偉達四季度收入60.5億美元,分析師預期60.2億美元;四季度數據中心收入36.2億美元,分析師預期38.6億美元;四季度遊戲收入18.3億美元,分析師預期16.0億美元;四季度每股收益0.88美元,分析師預期0.81美元;預計一季度收入65.0億美元正負2%,分析師預期63.5億美元。財報公佈後,週三收漲近0.5%的英偉達股價在美股盤後迅速拉昇,現已大漲8.7%,報225.6美元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.